---
layout: default
title: Dronedarone
description: "Dronedarone çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚é«˜è­‰æ“šç­‰ç´š L2ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 63
evidence_level: L1
indication_count: 10
---

# Dronedarone

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L2</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Dronedaroneï¼šå¾å¿ƒæˆ¿çº–ç¶­é¡«å‹•åˆ°ä¸­é¢¨ç–¾ç—…

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Dronedarone å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Dronedarone åŸæœ¬ç”¨æ–¼æ²»ç™‚é™£ç™¼æ€§æˆ–æŒçºŒæ€§å¿ƒæˆ¿çº–ç¶­é¡«å‹•/å¿ƒæˆ¿æ’²å‹•ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**ä¸­é¢¨ç–¾ç—… (stroke disorder)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **å¤šå€‹è‡¨åºŠè©¦é©—**å’Œ **å¤šç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | å¿ƒæˆ¿çº–ç¶­é¡«å‹•ã€å¿ƒæˆ¿æ’²å‹• |
| é æ¸¬æ–°é©æ‡‰ç—‡ | stroke disorderã€obsolete susceptibility to ischemic strokeã€ABri amyloidosisã€cerebrovascular disorderã€brain stem infarctionã€atrial fibrillation (disease)ã€sick sinus syndrome 2, autosomal dominantã€duodenal obstructionã€cerebral artery occlusionã€sarcoglycanopathy |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.97% |
| è­‰æ“šç­‰ç´š | L2 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 1 å¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |





## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. stroke disorder</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.97%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p><p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ"></p>
<p>Dronedarone æ˜¯ amiodarone çš„è¡ç”Ÿç‰©ï¼Œå…·æœ‰å¤šé€šé“é˜»æ–·ä½œç”¨ï¼Œèƒ½ç¶­æŒç«‡æ€§å¿ƒå¾‹ã€‚</p>
<p>å¿ƒæˆ¿çº–ç¶­é¡«å‹•æ˜¯ä¸­é¢¨çš„ä¸»è¦å±éšªå› ç´ ï¼Œé€éç¶­æŒç«‡æ€§å¿ƒå¾‹å¯æ¸›å°‘å¿ƒæˆ¿è¡€æ “å½¢æˆã€‚</p>
<p>ATHENA è©¦é©—çš„äº‹å¾Œåˆ†æé¡¯ç¤º dronedarone å¯é™ä½ä¸­é¢¨å’Œæš«æ™‚æ€§è…¦ç¼ºè¡€ç™¼ä½œé¢¨éšªï¼Œ</p>
<p>ä¸”ç ”ç©¶ç™¼ç¾å…¶å…·æœ‰ç¨ç«‹æ–¼æŠ—å¿ƒå¾‹ä¸æ•´ä½œç”¨ä¹‹å¤–çš„æŠ—å‡è¡€å’ŒæŠ—è¡€å°æ¿æ•ˆæ‡‰ã€‚</p>
<p></p></p>

<p><div class="key-takeaway"></p>
<p>æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01151137" target="_blank">NCT01151137</a></td><td>PHASE3</td><td>TERMINATED</td><td>3236</td><td>A Randomized, Double Blind, Placebo Controlled, Parallel Group Trial for Assessi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03489395" target="_blank">NCT03489395</a></td><td>PHASE2</td><td>COMPLETED</td><td>25</td><td>A Pilot Study on Edoxaban for the Resolution of Left Atrial Thrombosis in Patien...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02294955" target="_blank">NCT02294955</a></td><td>NA</td><td>UNKNOWN</td><td>152</td><td>Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04704050" target="_blank">NCT04704050</a></td><td>PHASE4</td><td>TERMINATED</td><td>22</td><td>Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Rec...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03993119" target="_blank">NCT03993119</a></td><td>N/A</td><td>COMPLETED</td><td>500</td><td>Non-Interventional, Cross-sectional Study to Describe NOACs Management in Elderl...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05279833" target="_blank">NCT05279833</a></td><td>N/A</td><td>COMPLETED</td><td>87810</td><td>SLR/NMA of MultaqÂ® vs Sotalol to Assess for Safety in Patients With Atrial Fibri...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01288352" target="_blank">NCT01288352</a></td><td>PHASE4</td><td>COMPLETED</td><td>2789</td><td>Early Therapy of Atrial Fibrillation for Stroke Prevention Trial (EAST).</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01266681" target="_blank">NCT01266681</a></td><td>NA</td><td>UNKNOWN</td><td>100</td><td>Amiodarone Compared to Dronedarone , Post Cardioversion Maintenance of Sinus</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02618577" target="_blank">NCT02618577</a></td><td>PHASE3</td><td>TERMINATED</td><td>2608</td><td>Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate E...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07242326" target="_blank">NCT07242326</a></td><td>N/A</td><td>NOT_YET_RECRUITING</td><td>1000</td><td>SNAP AF-52 - An Ambidirectional Observational Study to Assess Label-Concordant D...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01856075" target="_blank">NCT01856075</a></td><td>N/A</td><td>COMPLETED</td><td>1015</td><td>Relative Effectiveness of Dronedarone vs. Other Treatments of Atrial Fibrillatio...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07270848" target="_blank">NCT07270848</a></td><td>PHASE4</td><td>NOT_YET_RECRUITING</td><td>1898</td><td>A Multicenter Prospective Study on the Efficacy, Safety, and Quality of Life Imp...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03840291" target="_blank">NCT03840291</a></td><td>PHASE4</td><td>COMPLETED</td><td>36</td><td>Resolution of Thrombi in Left Atrial Appendage With Edoxaban</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06125925" target="_blank">NCT06125925</a></td><td>NA</td><td>RECRUITING</td><td>436</td><td>Catheter Ablation in Atrial Fibrillation Patients With Heart Failure With Preser...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05293080" target="_blank">NCT05293080</a></td><td>PHASE3</td><td>NOT_YET_RECRUITING</td><td>1746</td><td>Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STRO...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05130268" target="_blank">NCT05130268</a></td><td>PHASE4</td><td>COMPLETED</td><td>339</td><td>Pragmatic Randomized Clinical Trial of Early Dronedarone Versus Usual Care to Ch...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06096337" target="_blank">NCT06096337</a></td><td>NA</td><td>ACTIVE_NOT_RECRUITING</td><td>484</td><td>A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablatio...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05939076" target="_blank">NCT05939076</a></td><td>PHASE3</td><td>NOT_YET_RECRUITING</td><td>220</td><td>First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation - ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00911508" target="_blank">NCT00911508</a></td><td>NA</td><td>COMPLETED</td><td>2204</td><td>Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22166900/" target="_blank">22166900</a></td><td>2012</td><td>Article</td><td>Lancet (London, England)</td><td>Atrial fibrillation.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40387892/" target="_blank">40387892</a></td><td>2025</td><td>Article</td><td>Clinical research in cardiolog</td><td>Safety and efficacy of amiodarone and dronedarone for early rhythm control in EA...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22920480/" target="_blank">22920480</a></td><td>2012</td><td>Article</td><td>Current cardiology reviews</td><td>Stroke prevention in atrial fibrillation: concepts and controversies.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20730068/" target="_blank">20730068</a></td><td>2010</td><td>Article</td><td>Vascular health and risk manag</td><td>Dronedarone for the treatment of atrial fibrillation and atrial flutter: approva...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21930637/" target="_blank">21930637</a></td><td>2011</td><td>Article</td><td>American journal of health-sys</td><td>Drug-induced heart failure.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37777298/" target="_blank">37777298</a></td><td>2023</td><td>Article</td><td>The American journal of cardio</td><td>Chapter 2: Rate Versus Rhythm Control.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28992468/" target="_blank">28992468</a></td><td>2017</td><td>Article</td><td>Atherosclerosis</td><td>Dronedarone exerts anticoagulant and antiplatelet effects independently of its a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35293087/" target="_blank">35293087</a></td><td>2022</td><td>Article</td><td>European journal of heart fail</td><td>Dronedarone for the treatment of atrial fibrillation with concomitant heart fail...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28496906/" target="_blank">28496906</a></td><td>2013</td><td>Article</td><td>Journal of atrial fibrillation</td><td>Risk of Cardiovascular Events, Stroke, Congestive Heart Failure, Interstitial Lu...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22433576/" target="_blank">22433576</a></td><td>2012</td><td>Article</td><td>The Canadian journal of cardio</td><td>Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation g...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37485722/" target="_blank">37485722</a></td><td>2023</td><td>Article</td><td>Circulation. Arrhythmia and el</td><td>Dronedarone Versus Sotalol in Antiarrhythmic Drug-Naive Veterans With Atrial Fib...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33888353/" target="_blank">33888353</a></td><td>2021</td><td>Article</td><td>Clinical therapeutics</td><td>Evaluating the Risk of Digitalis Intoxication Associated With Concomitant Use of...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22082198/" target="_blank">22082198</a></td><td>2011</td><td>Article</td><td>The New England journal of med</td><td>Dronedarone in high-risk permanent atrial fibrillation.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37676022/" target="_blank">37676022</a></td><td>2024</td><td>Article</td><td>Journal of cardiovascular elec</td><td>Are antiarrhythmic agents indicated in premature ventricular complex-induced car...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24810388/" target="_blank">24810388</a></td><td>2014</td><td>Article</td><td>European heart journal</td><td>Edoxaban: a focused review of its clinical pharmacology.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25428811/" target="_blank">25428811</a></td><td>2015</td><td>Article</td><td>Kardiologia polska</td><td>Analysis of the cost-effectiveness of dronedarone versus amiodarone, propafenone...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24469871/" target="_blank">24469871</a></td><td>2013</td><td>Article</td><td>Cardiology journal</td><td>Efficacy and tolerability of dronedarone for patients with atrial fibrillation.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22576674/" target="_blank">22576674</a></td><td>2012</td><td>Article</td><td>Current hypertension reports</td><td>Recent clinical trials in atrial fibrillation in hypertensive patients.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38782070/" target="_blank">38782070</a></td><td>2024</td><td>Article</td><td>International journal of cardi</td><td>The effect of antiarrhythmic medications on the risk of cardiovascular outcomes ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19678722/" target="_blank">19678722</a></td><td>2009</td><td>Article</td><td>Journal of managed care pharma</td><td>Pharmacologic management of atrial fibrillation: established and emerging option...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. obsolete susceptibility to ischemic stroke</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.96%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. ABri amyloidosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.92%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. cerebrovascular disorder</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.71%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ6 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03993119" target="_blank">NCT03993119</a></td><td>N/A</td><td>COMPLETED</td><td>500</td><td>Non-Interventional, Cross-sectional Study to Describe NOACs Management in Elderl...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01288352" target="_blank">NCT01288352</a></td><td>PHASE4</td><td>COMPLETED</td><td>2789</td><td>Early Therapy of Atrial Fibrillation for Stroke Prevention Trial (EAST).</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01856075" target="_blank">NCT01856075</a></td><td>N/A</td><td>COMPLETED</td><td>1015</td><td>Relative Effectiveness of Dronedarone vs. Other Treatments of Atrial Fibrillatio...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06125925" target="_blank">NCT06125925</a></td><td>NA</td><td>RECRUITING</td><td>436</td><td>Catheter Ablation in Atrial Fibrillation Patients With Heart Failure With Preser...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05293080" target="_blank">NCT05293080</a></td><td>PHASE3</td><td>NOT_YET_RECRUITING</td><td>1746</td><td>Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STRO...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06096337" target="_blank">NCT06096337</a></td><td>NA</td><td>ACTIVE_NOT_RECRUITING</td><td>484</td><td>A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablatio...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22166900/" target="_blank">22166900</a></td><td>2012</td><td>Article</td><td>Lancet (London, England)</td><td>Atrial fibrillation.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22149318/" target="_blank">22149318</a></td><td>2011</td><td>Article</td><td>American journal of cardiovasc</td><td>Dronedarone and the incidence of stroke in patients with paroxysmal or persisten...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22682206/" target="_blank">22682206</a></td><td>2012</td><td>Article</td><td>Neurologia (Barcelona, Spain)</td><td>[Prevention of cardioembolic stroke].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20396635/" target="_blank">20396635</a></td><td>2010</td><td>Article</td><td>Clinical interventions in agin</td><td>Impact of dronedarone in atrial fibrillation and flutter on stroke reduction.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30528621/" target="_blank">30528621</a></td><td>2019</td><td>Article</td><td>International journal of cardi</td><td>Impact of dronedarone on the risk of myocardial infarction and stroke in atrial ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27693025/" target="_blank">27693025</a></td><td>2017</td><td>Article</td><td>Revista espanola de cardiologi</td><td>Concomitant Rivaroxaban and Dronedarone Administration in Patients With Nonvalvu...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21296333/" target="_blank">21296333</a></td><td>2011</td><td>Article</td><td>The American journal of cardio</td><td>Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibr...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25820938/" target="_blank">25820938</a></td><td>2015</td><td>Article</td><td>The Cochrane database of syste</td><td>Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibri...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25004988/" target="_blank">25004988</a></td><td>2014</td><td>Article</td><td>Current cardiology reviews</td><td>Are we at the goal line with the novel oral anticoagulants and have we reached t...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36398362/" target="_blank">36398362</a></td><td>2022</td><td>Article</td><td>Expert opinion on pharmacother</td><td>Pharmacotherapy for stroke prevention in nonvalvular atrial fibrillation: curren...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31898737/" target="_blank">31898737</a></td><td>2020</td><td>Article</td><td>Europace : European pacing, ar</td><td>Do amiodarone and dronedarone prevent thrombo-embolic stroke by treating the atr...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23709402/" target="_blank">23709402</a></td><td>2013</td><td>Article</td><td>Drugs &amp; aging</td><td>Atrial fibrillation in the elderly.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40295782/" target="_blank">40295782</a></td><td>2025</td><td>Article</td><td>Europace : European pacing, ar</td><td>Dronedarone provides effective early rhythm control: post-hoc analysis of the AT...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22082198/" target="_blank">22082198</a></td><td>2011</td><td>Article</td><td>The New England journal of med</td><td>Dronedarone in high-risk permanent atrial fibrillation.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22920480/" target="_blank">22920480</a></td><td>2012</td><td>Article</td><td>Current cardiology reviews</td><td>Stroke prevention in atrial fibrillation: concepts and controversies.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22366819/" target="_blank">22366819</a></td><td>2012</td><td>Article</td><td>Cardiovascular drugs and thera</td><td>Pleiotropic effects of dronedarone on ischemia/reperfusion injury in heart and b...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21323608/" target="_blank">21323608</a></td><td>2011</td><td>Article</td><td>Expert opinion on pharmacother</td><td>Antiarrhythmic drugs for atrial fibrillation.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37000581/" target="_blank">37000581</a></td><td>2023</td><td>Article</td><td>Europace : European pacing, ar</td><td>Cardiovascular outcomes in patients with atrial fibrillation concomitantly treat...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29776576/" target="_blank">29776576</a></td><td>2018</td><td>Article</td><td>International journal of cardi</td><td>Safety of apixaban in combination with dronedarone in patients with atrial fibri...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30578095/" target="_blank">30578095</a></td><td>2019</td><td>Article</td><td>International journal of cardi</td><td>Apples will never be oranges, but when you go fishing you may get a bite.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. brain stem infarction</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.71%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. sick sinus syndrome 2, autosomal dominant</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.63%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. duodenal obstruction</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.56%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. cerebral artery occlusion</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.44%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ1 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05130268" target="_blank">NCT05130268</a></td><td>PHASE4</td><td>COMPLETED</td><td>339</td><td>Pragmatic Randomized Clinical Trial of Early Dronedarone Versus Usual Care to Ch...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. sarcoglycanopathy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.43%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. Wildervanck syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.37%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| 1 å¼µè¨±å¯è­‰ | æ±ºå¥ˆé”éš†é¹½é…¸é¹½ | å£æœåŠ‘å‹ | é™£ç™¼æ€§æˆ–æŒçºŒæ€§å¿ƒæˆ¿çº–ç¶­é¡«å‹•/å¿ƒæˆ¿æ’²å‹•ï¼Œé™ä½å¿ƒæˆ¿é¡«å‹•ä½é™¢é¢¨éšª |

## å®‰å…¨æ€§è€ƒé‡

- **é»‘æ¡†è­¦å‘Š**ï¼šæ°¸ä¹…æ€§å¿ƒæˆ¿çº–ç¶­é¡«å‹•ã€åš´é‡å¿ƒè¡°ç«­æ‚£è€…ç¦ç”¨
- **ä¸»è¦ä¸è‰¯åæ‡‰**ï¼šè…¹ç€‰ã€å™å¿ƒã€è…¹ç—›ã€è¡€æ¸…è‚Œé…å‡é«˜
- **è‚æ¯’æ€§**ï¼šç½•è¦‹ä½†åš´é‡ï¼Œéœ€ç›£æ¸¬è‚åŠŸèƒ½
- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼šèˆ‡ digoxin ä½µç”¨æ™‚æœƒå¢åŠ  digoxin è¡€ä¸­æ¿ƒåº¦




### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**è‘¡è„æŸšæ±** ğŸŸ¢ Minor
- å½±éŸ¿ï¼šå½±éŸ¿è—¥ç‰©ä»£è¬ã€‚å¯èƒ½å¢åŠ è—¥ç‰©è¡€ä¸­æ¿ƒåº¦ã€‚
- å»ºè­°ï¼šå»ºè­°é¿å…ä½µç”¨ã€‚é¿å…é£Ÿç”¨è‘¡è„æŸšæˆ–è‘¡è„æŸšæ±ã€‚

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**è–ç´„ç¿°è‰ï¼ˆè²«è‘‰é€£ç¿¹ï¼‰** ğŸ”´ Major
- å½±éŸ¿ï¼šè–ç´„ç¿°è‰é™ä½ Dronedarone è¡€ä¸­æ¿ƒåº¦
- å»ºè­°ï¼šç¦æ­¢ä½µç”¨


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Cardiomyopathies** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
Dronedarone é€éç¶­æŒç«‡æ€§å¿ƒå¾‹å’Œæ½›åœ¨çš„æŠ—è¡€æ “æ©Ÿåˆ¶ï¼Œå¯èƒ½å°ä¸­é¢¨é é˜²æœ‰æ•ˆã€‚
ATHENA è©¦é©—å·²é¡¯ç¤ºå…¶åœ¨ä¸­é¢¨/TIA é é˜²æ–¹é¢çš„ç›Šè™•ï¼Œä½†éœ€æ³¨æ„é©æ‡‰ç—‡é™åˆ¶ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- æ’é™¤æ°¸ä¹…æ€§å¿ƒæˆ¿çº–ç¶­é¡«å‹•å’Œåš´é‡å¿ƒè¡°ç«­æ‚£è€…
- åš´æ ¼çš„è‚åŠŸèƒ½ç›£æ¸¬è¨ˆç•«
- èˆ‡æŠ—å‡è¡€è—¥ç‰©ä½µç”¨ç­–ç•¥çš„å„ªåŒ–ç ”ç©¶

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Carboplatin]({{ "/drugs/carboplatin/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Hydroxyurea]({{ "/drugs/hydroxyurea/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Hydroxyprogesterone Caproate]({{ "/drugs/hydroxyprogesterone_caproate/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Oteracil]({{ "/drugs/oteracil/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Prednisone]({{ "/drugs/prednisone/" | relative_url }}) - è­‰æ“šç­‰ç´š L2

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Dronedaroneè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/dronedarone/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_dronedarone,
  title = {Dronedaroneè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/dronedarone/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
